Nephrology Dialysis Transplantation

Article	Citations
COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration	292
Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA	244
Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres	182
Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey	133
Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls	109
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics	104
European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D	96
ADAM17 inhibition may exert a protective effect on COVID-19	94
How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion	90
High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients	81
Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak	81
Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study	77
Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES)	71
Roxadustat for anemia in patients with end-stage renal disease incident to dialysis	67
An overview of frailty in kidney transplantation: measurement, management and future considerations	66
Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center	66
Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS)	64
COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study	60
Does dietary potassium intake associate with hyperkalemia in patients with chronic kidney disease?	58
Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice	57
Targeting acute kidney injury in COVID-19	55
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial	53
Early vascular ageing in chronic kidney disease: impact of inflammation, vitamin K, senescence and genomic damage	52
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in a haemodialysis cohort	51
Renal gluconeogenesis: an underestimated role of the kidney in systemic glucose metabolism	51

Physical activity in chronic kidney disease and the EXerCise Introduction To Enhance trial	46
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease	46
Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone	44
Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study	44
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAP	44
At least 156 reasons to prioritize COVID-19 vaccination in patients receiving in-centre haemodialysis	44
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)	43
The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria	42
An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disea	41
Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort	40
The impact of chronic kidney disease Stages 3–5 on pregnancy outcomes	40
Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers	40
Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players	39
Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results	39
Volume overload in hemodialysis: diagnosis, cardiovascular consequences, and management	39
Clinical and predictive value of simplified creatinine index used as muscle mass surrogate in end-stage kidney disease haemodialysis patients—results from the international MONitoring Dialysis Outcome	38
Nephrotic syndrome and vasculitis following SARS-CoV-2 vaccine: true association or circumstantial?	38
Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study	35
Impact of longer term phosphorus control on cardiovascular mortality in hemodialysis patients using an area under the curve approach: results from the DOPPS	34
Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases	34
Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease	34
Prevalence and outcomes of hyponatremia and hypernatremia in patients hospitalized with COVID-19	34
Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study	33
Acute kidney injury and urinary biomarkers in hospitalized patients with coronavirus disease-2019	33
Performance of creatinine-based equations to estimate glomerular filtration rate in White and Black populations in Europe, Brazil and Africa	33
Idiopathic retroperitoneal fibrosis: an update for nephrologists	32
Free p-cresyl sulfate shows the highest association with cardiovascular outcome in chronic kidney disease	32
How to tackle health literacy problems in chronic kidney disease patients? A systematic review to identify promising intervention targets and strategies	31
PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab	31
Myostatin and muscle atrophy during chronic kidney disease	31
Impact of first-wave COronaVIrus disease 2019 infection in patients on haemoDIALysis in Alsace: the observational COVIDIAL study	30
High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients	30
SIRT2 is involved in cisplatin-induced acute kidney injury through regulation of mitogen-activated protein kinase phosphatase-1	30
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results	30
Urine proteomics for prediction of disease progression in patients with IgA nephropathy	29
The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant	29
Metagenomic profiling of gut microbiome in early chronic kidney disease	28
Tissue sodium concentrations in chronic kidney disease and dialysis patients by lower leg sodium-23 magnetic resonance imaging	28
Bone evaluation in paediatric chronic kidney disease: clinical practice points from the European Society for Paediatric Nephrology CKD-MBD and Dialysis working groups and CKD-MBD working group of the	28
Acute kidney injury in patients with COVID-19: an update on the pathophysiology	27
What should European nephrology do with the new CKD-EPI equation?	27
Contribution of uremic dysbiosis to insulin resistance and sarcopenia	27
Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort	27
Health-related quality of life and symptoms of conservative care versus dialysis in patients with end-stage kidney disease: a systematic review	27
Early versus late acute kidney injury among patients with COVID-19—a multicenter study from Wuhan, China	26
Effects of calcitriol and paricalcitol on renal fibrosis in CKD	26
Measured sodium excretion is associated with CKD progression: results from the KNOW-CKD study	26
Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors	26
Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium	25
Mapping health-related quality of life after kidney transplantation by group comparisons: a systematic review	25

Tissue sodium stores in peritoneal dialysis and hemodialysis patients determined by sodium-23 magnetic resonance imaging	25
SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, ‘diabetic nephropathy’, IgA nephropathy and podocytopathies with FSGS lesions	24
Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients	24
Management of obesity in kidney transplant candidates and recipients: A clinical practice guideline by the DESCARTES Working Group of ERA	24
Genetics-first approach improves diagnostics of ESKD patients <50 years old	24
Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?	24
Renin–angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease	24
Wearable health devices and personal area networks: can they improve outcomes in haemodialysis patients?	24
Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease	23
The cholinergic anti-inflammatory pathway in chronic kidney disease—review and vagus nerve stimulation clinical pilot study	23
International prescribing patterns and polypharmacy in older people with advanced chronic kidney disease: results from the European Quality study	23
Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis	23
The renal replacement therapy landscape in 2030: reducing the global cardiovascular burden in dialysis patients	22
Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion	22
Effect of hemodiafiltration on measured physical activity: primary results of the HDFIT randomized controlled trial	22
Effects of Oxalobacter formigenes in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a Phase II study	22
The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes Cardi	22
Cognitive disorders in patients with chronic kidney disease: specificities of clinical assessment	21
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS	21
Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2	21
ERACODA: the European database collecting clinical information of patients on kidney replacement therapy with COVID-19	21
Persistence of antibody response to SARS-CoV-2 in a cohort of haemodialysis patients with COVID-19	21
Kidney disease pathways, options and decisions: an environmental scan of international patient decision aids	21
Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: a 2-year observational study	20
Hypoxia in chronic kidney disease: towards a paradigm shift?	20
Magnesium to prevent kidney disease–associated vascular calcification: crystal clear?	20
Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis	20
Nutritional status, hyperkalaemia and attainment of energy/protein intake targets in haemodialysis patients following plant-based diets: a longitudinal cohort study	20
Early net ultrafiltration rate and mortality in critically ill patients receiving continuous renal replacement therapy	20
Renal denervation in patients with versus without chronic kidney disease: results from the Global SYMPLICITY Registry with follow-up data of 3 years	20
Urinary excretion of epidermal growth factor and rapid loss of kidney function	19
Bleeding risk of haemodialysis and peritoneal dialysis patients	19
Dynapaenia and sarcopaenia in chronic haemodialysis patients: do muscle weakness and atrophy similarly influence poor outcome?	19
Removing race from the CKD-EPI equation and its impact on prognosis in a predominantly White European population	19
Young adults have worse kidney transplant outcomes than other age groups	19
Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis	19
Renal transplant outcomes in amyloidosis	19
Sodium, volume and pressure control in haemodialysis patients for improved cardiovascular outcomes	19
The European Green Deal and nephrology: a call for action by the European Kidney Health Alliance	19
Renal denervation: where do we stand and what is the relevance to the nephrologist?	18
LB002ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)	18
Dietary plant and animal protein intake and decline in estimated glomerular filtration rate among elderly women: a 10-year longitudinal cohort study	18
Patient-reported factors influencing the choice of their kidney replacement treatment modality	18
The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation	18
Increasing incidence and improved survival in ANCA-associated vasculitis—a Danish nationwide study	18
Recruitment and retention in clinical trials in chronic kidney disease: report from national workshops with patients, caregivers and health professionals	18
Diffusion magnetic resonance imaging detects an increase in interstitial fibrosis earlier than the decline of renal function	18
Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection	18
Lactobacillus rhamnosus L34 attenuates chronic kidney disease progression in a 5/6 nephrectomy mouse model through the excretion of anti-inflammatory molecules	18
The transition clinic in chronic kidney disease care	18
Assisted peritoneal dialysis and transfer to haemodialysis: a cause-specific analysis with data from the RDPLF	18
Impact of the implementation of an assisted peritoneal dialysis service on peritoneal dialysis initiation	18
Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials	18
Muscle protein turnover and low-protein diets in patients with chronic kidney disease	18
Circulating plasmablasts and high level of BAFF are hallmarks of minimal change nephrotic syndrome in adults	18
COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection	17
Precision medicine approaches for diabetic kidney disease: opportunities and challenges	17
Protein carbamylation and chronic kidney disease progression in the Chronic Renal Insufficiency Cohort Study	17
Tubulointerstitial nephritis and uveitis syndrome: a systematic review	17
Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE	17
Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study	17
Klotho is a novel therapeutic target in peritoneal fibrosis via Wnt signaling inhibition	17
Fibrosis and cancer: shared features and mechanisms suggest common targeted therapeutic approaches	17
Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia	17
COVID-19 vaccination in haemodialysis patients: good things come in threes…	17
Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials	17
Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p.(Gly624Asp): a prospective cohort study	16
Climate change and nephrology	16
Metabolic dysfunction–associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease	16
Tubular phosphate handling: references from child to adulthood in the era of standardized serum creatinine	16
Interim analysis of the COSA (COVID-19 patients treated with the Seraph® 100 Microbind® Affinity filter) registry	16
Distal renal tubular acidosis: ERKNet/ESPN clinical practice points	16
Armed conflicts and kidney patients: a consensus statement from the Renal Disaster Relief Task Force of the ERA	16
Water intake and progression of chronic kidney disease: the CKD-REIN cohort study	16
The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis	16
Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study	15
Renal function decline in older men and women with advanced chronic kidney disease—results from the EQUAL study	15
Efficacy and safety of combination therapy with sodium–glucose cotransporter 2 inhibitors and renin–angiotensin system blockers in patients with type 2 diabetes: a systematic review and meta-analysis	15
The consequences of altered microbiota in immune-related chronic kidney disease	15
Risk factors for venous thromboembolism in patients with nephrotic syndrome: a retrospective cohort study	15

Association of subjective global assessment of nutritional status with gut microbiota in hemodialysis patients: a case–control study	15
Causal effects of physical activity or sedentary behaviors on kidney function: an integrated population-scale observational analysis and Mendelian randomization study	15
Does kidney transplantation with a standard or expanded criteria donor improve patient survival? Results from a Belgian cohort	15
Heart failure in chronic kidney disease: the emerging role of myocardial fibrosis	15
The Prepare for Kidney Care Study: prepare for renal dialysis versus responsive management in advanced chronic kidney disease	14
Outcome and effect of vaccination in SARS-CoV-2 Omicron infection in hemodialysis patients: a cohort study	14
Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis	14
Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors	14
Pre-eclampsia is a valuable opportunity to diagnose chronic kidney disease: a multicentre study	14
Serum hemoglobin concentration and risk of renal function decline in early stages of diabetic kidney disease: a nationwide, biopsy-based cohort study	14
Acidosis, cognitive dysfunction and motor impairments in patients with kidney disease	14
A call for harmonization of European kidney care: dialysis reimbursement and distribution of kidney replacement therapies	14
Phosphoinositide 3-kinase γ deficiency attenuates kidney injury and fibrosis in angiotensin II–induced hypertension	14
DNA methylation profiling identifies epigenetic differences between early versus late stages of diabetic chronic kidney disease	14
Precision medicine in Fabry disease	14
International peritoneal dialysis training practices and the risk of peritonitis	14
Peripheral neuropathy: an important contributor to physical limitation and morbidity in stages 3 and 4 chronic kidney disease	14
Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage	14
Systematic review of the nuclear factor erythroid 2-related factor 2 (NRF2) system in human chronic kidney disease: alterations, interventions and relation to morbidity	14
Humoral response after the fourth dose of the SARS-CoV-2 vaccine in the CKD spectrum: a prespecified analysis of the SENCOVAC study	14
LB004A RANDOMIZED, CONTROLLED TRIAL OF RITUXIMAB VERSUS AZATHIOPRINE AFTER INDUCTION OF REMISSION WITH RITUXIMAB FOR PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND RELAPSING DISEASE	14
The clinical characteristics of coronavirus-associated nephropathy	14
Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study	13
CONVINCE in the context of existing evidence on haemodiafiltration	13
Long-term risks after kidney donation: how do we inform potential donors? A survey from DESCARTES and EKITA transplantation working groups	13
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study	13
β-blocker dialyzability and the risk of mortality and cardiovascular events in patients undergoing hemodialysis	13
Clinical events and patient-reported outcome measures during CKD progression: findings from the Chronic Renal Insufficiency Cohort Study	13
Evidence of an intestinal phosphate transporter alternative to type IIb sodium-dependent phosphate transporter in rats with chronic kidney disease	13
Humoral response after SARS-CoV-2 vaccination in patients undergoing maintenance haemodialysis: loss of immunity, third dose and non-responders	13
Pre-kidney transplant unintentional weight loss leads to worse post-kidney transplant outcomes	13
The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes	13
The receptor activator of nuclear factor κΒ ligand receptor leucine-rich repeat-containing G-protein-coupled receptor 4 contributes to parathyroid hormone-induced vascular calcification	13
Decreased kidney function and agricultural work: a cross-sectional study in middle-aged adults from Tierra Blanca, Mexico	13
Are all erythropoiesis-stimulating agents created equal?	13
Routine serum biomarkers, but not dual-energy X-ray absorptiometry, correlate with cortical bone mineral density in children and young adults with chronic kidney disease	13
Chronic kidney disease, physical activity and cognitive function in older adults—results from the National Health and Nutrition Examination Survey (2011–2014)	13
Association of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion in kidney stone formers	12
Albuminuria as a risk factor for mild cognitive impairment and dementia—what is the evidence?	12
Types of erythropoiesis-stimulating agents and risk of end-stage kidney disease and death in patients with non-dialysis chronic kidney disease	12
Dietary magnesium supplementation inhibits abdominal vascular calcification in an experimental animal model of chronic kidney disease	12
Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia	12
Factors influencing fertility rates in Australian women receiving kidney replacement therapy: analysis of linked Australia and New Zealand Dialysis and Transplant Registry and perinatal data over 22 y	12
Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice	12
Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis	12
Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis	12
Effect of fructooligosaccharide on endothelial function in CKD patients: a randomized controlled trial	12
Time-dependent evolution of IgG antibody levels after first and second dose of mRNA-based SARS-CoV-2 vaccination in haemodialysis patients: a multicentre study	12
Laxative use in patients with advanced chronic kidney disease transitioning to dialysis	12
Regenerating tubular epithelial cells of the kidney	12
Survival of patients who opt for dialysis versus conservative care: a systematic review and meta-analysis	12
Physical activity and risk of cardiovascular events and all-cause mortality among kidney transplant recipients	12
Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients: seroconversion and presence of neutralizing antibodies	12
The reasons for a clinical trial on incremental haemodialysis	12
Screening of Fabry disease in patients with chronic kidney disease in Japan	11
Novel in vitro assays to detect circulating permeability factor(s) in idiopathic focal segmental glomerulosclerosis	11
Lessons learned during the war in Ukraine: a report from the Renal Disaster Relief Task Force of the ERA	11
Recommendations for the management of patients with immune-mediated kidney disease during the severe acute respiratory syndrome coronavirus 2 pandemic	11
Long-term outcome of the survivors of infantile hypercalcaemia with CYP24A1 and SLC34A1 mutations	11
Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis	11
RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease	11
Factors associated with sex differences in the risk of kidney stones	11
mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients?	11
MO039THE 24-WEEK INTERIM ANALYSIS RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II STUDY OF ATACICEPT IN PATIENTS WITH IGA NEPHROPATHY AND PERSISTENT PROTEINURIA	11
Patterns of renal osteodystrophy 1 year after kidney transplantation	11
Prognostic models for chronic kidney disease: a systematic review and external validation	11
Semiquantitative assessed proteinuria and risk of heart failure: analysis of a nationwide epidemiological database	11
Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment	11
Chronic hypoxia exacerbates diabetic glomerulosclerosis through mesangiolysis and podocyte injury in db/db mice	11
Can the assessment of ultrasound lung water in haemodialysis patients be simplified?	11
Overcoming barriers in the design and implementation of clinical trials for acute kidney injury: a report from the 2020 Kidney Disease Clinical Trialists meeting	10
Perspectives on mental health among patients receiving dialysis	10
Combining phosphate binder therapy with vitamin K2 inhibits vascular calcification in an experimental animal model of kidney failure	10
COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab	10
Prolonged patient survival after implementation of a continuous quality improvement programme empowered by digital transformation in a large dialysis network	10
Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy	10
Clinical and genetic spectra of autosomal dominant tubulointerstitial kidney disease	10
Itching in dialysis patients: impact on health-related quality of life and interactions with sleep problems and psychological symptoms—results from the RENINE/PROMs registry	10
The incidence and prevalence of IgA nephropathy in Europe	10
Serum levels of IL-6, IL-8 and IL-10 and risks of end-stage kidney disease and mortality	10
Using a generic definition of cachexia in patients with kidney disease receiving haemodialysis: a longitudinal (pilot) study	10
Recent findings on the clinical utility of renal magnetic resonance imaging biomarkers	10
Drug prescription in patients with chronic kidney disease: a true challenge	10
Assessment of a modified renal angina index for AKI prediction in critically ill adults	10
Don’t forget the zinc	10
Asystole episodes and bradycardia in patients with end-stage renal disease	10
Temporal trends in the quality of deceased donor kidneys and kidney transplant outcomes in Europe: an analysis by the ERA-EDTA Registry	10
Effects of the chymase inhibitor fulacimstat in diabetic kidney disease—results from the CADA DIA trial	10
The problem with transferrin saturation as an indicator of iron ‘sufficiency’ in chronic kidney disease	10
Long-term outcomes of COVID-19 survivors with hospital AKI: association with time to recovery from AKI	10
Effects of bariatric surgery on kidney diseases, cardiovascular diseases, mortality and severe hypoglycaemia among patients with Type 2 diabetes mellitus	10
Sodium intake and progression of chronic kidney disease—has the time finally come to do the impossible: a prospective randomized controlled trial?	10
Immune checkpoint inhibitor–associated hypercalcaemia	10
Sex difference in ambulatory blood pressure control associates with risk of ESKD and death in CKD patients receiving stable nephrology care	10
Weekly seroconversion rate of the mRNA-1273 SARS-CoV-2 vaccine in haemodialysis patients	10